Prior view $200M-$230M. Backs FY23 CapEx view $50M-$60M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMRX:
- AMRX Upcoming Earnings Report: What to Expect?
- Amneal Pharmaceuticals submits ANDA to FDA for three key complex generics
- Amneal (NYSE: AMRX) Tanks after Receiving Complete Response Letter from the U.S. FDA
- Amneal Complete Response Letter a surprise, says Barclays
- Amneal Pharmaceuticals announces launch of authorized generic for Xyrem